We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+3.01%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$367M
AUM Growth
-$150M
Cap. Flow
-$146M
Cap. Flow %
-39.8%
Top 10 Hldgs %
78.79%
Holding
53
New
7
Increased
9
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$8.62M
2
NVO
Novo Nordisk
NVO
+$6.67M
3
VKTX icon
Viking Therapeutics
VKTX
+$4.69M
4
RVMD icon
Revolution Medicines
RVMD
+$4.18M
5
MRUS
Merus
MRUS
+$1.57M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$54.8M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.42M
3
APGE icon
Apogee Therapeutics
APGE
+$2.3M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.06M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$1.49M

Sector Composition

Rank Sector Weight
1 Healthcare 96.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.22B
$1.57M 0.43%
40,000
– –
CNTA
27
DELISTED
Centessa Pharmaceuticals
CNTA
$1.29M 0.35%
+80,380
New +$985K
EYPT icon
28
EyePoint Inc
EYPT
$1.03B
$1.25M 0.34%
156,300
+54,800
+54% +$481K
CRL icon
29
Charles River Laboratories
CRL
$12.6B
$1.24M 0.34%
6,305
-600
-9% -$125K
IONS icon
30
Ionis Pharmaceuticals
IONS
$9.01B
$1.22M 0.33%
30,479
-32,000
-51% -$1.49M
KROS icon
31
Keros Therapeutics
KROS
$198M
$1.16M 0.32%
20,000
– –
KURA icon
32
Kura Oncology
KURA
$817M
$1.12M 0.3%
57,178
– –
ASND icon
33
Ascendis Pharma A/S
ASND
$16B
$1.11M 0.3%
7,440
– –
ANNX icon
34
Annexon
ANNX
$880M
$1.02M 0.28%
172,226
+24,741
+17% +$147K
CRBP icon
35
Corbus Pharmaceuticals
CRBP
$177M
$978K 0.27%
47,400
+27,400
+137% +$1.4M
SLN
36
Silence Therapeutics
SLN
$531M
$954K 0.26%
52,476
– –
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.77B
$929K 0.25%
48,263
– –
NAMS icon
38
NewAmsterdam Pharma
NAMS
$3.21B
$901K 0.25%
54,285
– –
ALEC icon
39
Alector
ALEC
$165M
$901K 0.25%
+193,317
New +$1.04M
IRON icon
40
Disc Medicine
IRON
$3.03B
$660K 0.18%
13,440
– –
LRMR icon
41
Larimar Therapeutics
LRMR
$426M
$593K 0.16%
90,490
– –
SLRN
42
DELISTED
ACELYRIN
SLRN
$459K 0.13%
+93,114
New +$481K
MDGL icon
43
Madrigal Pharmaceuticals
MDGL
$11.9B
$330K 0.09%
1,557
– –
SMMT icon
44
Summit Therapeutics
SMMT
$10.8B
$318K 0.09%
+14,512
New +$203K
QTTB icon
45
Q32 Bio
QTTB
$490M
$210K 0.06%
+4,705
New +$173K
APGE icon
46
Apogee Therapeutics
APGE
$10.2B
– –
-58,400
Closed -$2.3M
INSM icon
47
PUT
Insmed
INSM
$21.5B
– –
-110,000
Closed -$7.37M
MRK icon
48
Merck
MRK
$317B
– –
-442,504
Closed -$54.8M
NVO
49
PUT
Novo Nordisk
NVO
$197B
– –
-310,000
Closed -$44.2M
OCUL icon
50
Ocular Therapeutix
OCUL
$1.87B
– –
-500,000
Closed -$3.42M
1
2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
DAC
Dividend Assets Capital Ridgeland, South Carolina $501M AUM 13.71% 1-Year Est. Return

Artia Global Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Artia Global Partners held 53 positions worth $367M, down 29% from $517M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Artia Global Partners withdrew a net $146M in Q3 2024, closing 8 positions and reducing 5 holdings. Its most notable exit was Merck, an estimated $54.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 75% a quarter earlier.

Against the trend, Artia Global Partners opened a new position in Revolution Medicines worth $4.35M.

  • Artia Global Partners's largest Q3 2024 buy was Revolution Medicines: 95,885 shares worth $4.35M.
  • Artia Global Partners added most to Soleno Therapeutics in Q3 2024, an estimated $8.62M increase.
  • Artia Global Partners's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $2.06M.
  • Artia Global Partners fully exited Merck in Q3 2024, selling an estimated $54.8M.
  • Artia Global Partners's ten largest holdings make up 79% of its $367M portfolio in Q3 2024.
  • Artia Global Partners opened 7 new positions and closed 8 in Q3 2024.
  • Artia Global Partners's portfolio value fell 29% quarter-over-quarter to $367M.

Based on Artia Global Partners's 13F filing for Q3 2024, filed 14 Nov 2024.